
Overview
Israel medical tech firm's Q4 revenue slightly missed analyst expectations, EPS met estimates
Company's Q4 revenue grew 6% yr/yr to $103.9 mln
Returned $127.4 mln to shareholders through share repurchases in 2025
Outlook
InMode expects 2026 revenue between $365 mln and $375 mln
Company anticipates non-GAAP EPS between $1.43 and $1.48 for 2026
InMode plans to launch two new laser-based platforms in 2026
Result Drivers
EUROPEAN GROWTH - Record revenue in European operations contributed to Q4 growth, per CFO Yair Malca
NORTH AMERICA STABILIZATION - Co sees early signs of stabilization in North America despite ongoing challenges, per CEO Moshe Mizrahy
LEADERSHIP CHANGES - Refreshed sales and post-sales leadership teams in North America aim to enhance service capabilities, per President Michael Dennison
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Miss* | $103.85 mln | $104.40 mln (8 Analysts) |
Q4 EPS | Meet | $0.42 | $0.42 (7 Analysts) |
Q4 Net Income | Slight Miss* | $27.03 mln | $27.20 mln (5 Analysts) |
Q4 Gross Margin |
| 78.00% |
|
Q4 Pretax Profit | Beat | $31.29 mln | $29.98 mln (6 Analysts) |
Q4 Operating Expenses |
| $55.31 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Inmode Ltd is $16.00, about 5.8% above its February 9 closing price of $15.12
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago
Press Release: ID:nPn8kfg7Ja
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.